Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Gale, Robert Peter  [Clear All Filters]
Journal Article
Koreth J, Pidala J, Perez WS, H Deeg J, Garcia-Manero G, Malcovati L, Cazzola M, Park S, Itzykson R, Ades L, et al. Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. J Clin Oncol. 2013.
Tamari R, McLornan DP, Ahn KWoo, Estrada-Merly N, Hernández-Boluda JCarlos, Giralt SA, Palmer JM, Gale RPeter, DeFilipp Z, Marks D, et al. A Simple Prognostic System in Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplant: A CIBMTR/EBMT analysis. Blood Adv. 2023.
Scott EC, Hari P, Kumar S, Fraser R, Davila O, Shah N, Gale RPeter, Díaz MÁngel, Agrawal V, Cornell RF, et al. Staging Systems for Newly Diagnosed Myeloma Patients undergoing Autologous Hematopoietic Cell Transplant: The Revised International Staging System shows the most Differentiation between Groups. Biol Blood Marrow Transplant. 2018.
Kegyes D, Jitaru C, Ghiaur G, Ciurea S, Hoelzer D, Tomuleasa C, Gale RPeter. Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia. Blood Rev. 2023:101042.
Zhang X, Gale RPeter, Liu B, Huang J, Zhang Y, Du X, Weng J, Li W, Xu N, Liu X, et al. Validation of the imatinib-therapy failure model. Leukemia. 2023.
Ren J, Lin K, Xu J, Lu Q, Luo Y, Lin C, Lu J, Weng Y, Zhang Y, Chen Z, et al. When is the best time and grade to start ruxolitinib in corticosteroid-refractory acute graft-versus-host-disease: A multi-center research. Clin Transplant. 2023:e15195.
Gale RPeter, Welsh J, P Karam A. Why are haematopoietic stem cells in the bone marrow: ontology recapitulates phylogeny. Leukemia. 2023.
Jiang Q, Liu Z-C, Zhang S-X, Gale RPeter. Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia. J Cancer Res Clin Oncol. 2016.

Pages